The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes
Open accessAbstract
Canagliflozin reduced kidney disease progression in participants with type 2 diabetes in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. This analysis explored potential mediators of the effects of canagliflozin on kidney outcomes. The percent mediating effect of 18 biomarkers indicative of disease was determined by comparing the hazard ratios for the effect of randomized treatment from an unadjusted model and from a model adjusting for the average post-randomization level of each biomarker. Multivariable analyses assessed the joint effects of biomarkers that mediated most strongly in univariable analyses. The kidney outcome was defined as a composite of 40% estimated glomerular filtration rate decline, end-stage kidney disease, or death due to kidney disease. Nine biomarkers (systolic blood pressure [8.9% of effect explained], urinary albumin:creatinine ratio [UACR; 23.9%], gamma glutamyltransferase [4.1%], hematocrit [51.1%], hemoglobin [41.3%], serum albumin [19.5%], erythrocytes [56.7%], serum urate [35.4%], and urine pH [7.5%]) individually mediated the effect of canagliflozin on the kidney outcome. In a parsimonious multivariable model, erythrocyte concentration, serum urate, and systolic blood pressure maximized cumulative mediation (115%). Mediating effects of UACR, but not other mediators, were highly dependent upon the baseline level of UACR: UACR mediated 42% and 7% of the effect in those with baseline UACR 30 mg/g or more and under 30 mg/g, respectively. The identified mediators support existing hypothesized mechanisms for the prevention of kidney outcomes with sodium glucose co-transporter 2 inhibitors. Thus, the disparity in mediating effects across baseline UACR subgroups suggests that the mechanism for kidney protection with canagliflozin may vary across patient subgroups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Reduction in albuminuria is also important to evaluate the efficacy of medications prescribed for kidney protection, as both SGLT2 inhibitors and finerenone have shown that the majority of their beneficial effect is mediated by reduction in albuminuria (42,43).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [43]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationMacKinnon, D. P., Fairchild, A. J., & Fritz, M. S. (2007) · Annual Review of Psychology · doi:10.1146/annurev.psych.58.110405.085542 · Cited by 5,688
Introduction to Statistical Mediation Analysis
MacKinnon, D. P. (2012) · doi:10.4324/9780203809556 · Cited by 5,618
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845 · cited 1×
“T he CANagliflozin cardioVascular Assessment Study (CANVAS) Program reported that the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin reduces the risk of clinically important kidney outcomes in patients with type 2 diabetes with established cardiovascular disease or those at high cardiovascular risk.(1)…”
BackgroundSurrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Self-citationPathophysiology of Progressive Nephropathies
Remuzzi, G., & Bertani, T. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811123392007 · Cited by 1,258
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
Mediation analysis in epidemiology: methods, interpretation and bias
Richiardi, L., Bellocco, R., & Zugna, D. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dyt127 · Cited by 822
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740
Mosenzon, O., Wiviott, S. D., Cahn, A., Rozenberg, A., Yanuv, I., Goodrich, E. L., Murphy, S. A., Heerspink, H. J. L., Zelniker, T. A., Dwyer, J. P., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30180-9 · Cited by 684
Self-citationRenal, metabolic and cardiovascular considerations of SGLT2 inhibition
DeFronzo, R. A., Norton, L., & Abdul‐Ghani, M. A. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.170 · Cited by 588
Effects of Allopurinol on the Progression of Chronic Kidney Disease
Badve, S. V., Pascoe, E. M., Tiku, A., Boudville, N. C., Brown, F. G., Cass, A., Clarke, P., Dalbeth, N., Day, R. O., de Zoysa, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915833 · Cited by 483
Self-citationHeerspink, H. J. L., Perco, P., Mulder, S., Leierer, J., Hansen, M. K., Heinzel, A., & Mayer, G. (2019) · Diabetologia · doi:10.1007/s00125-019-4859-4 · Cited by 457
Self-citationHeerspink, H. J. L., Greene, T., Tighiouart, H., Gansevoort, R. T., Coresh, J., Simon, A. L., Chan, T. M., Hou, F. F., Lewis, J. B., Locatelli, F., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30314-0 · Cited by 397
Self-citationSerum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes
Doria, A., Gałecki, A. T., Spino, C., Pop‐Busui, R., Cherney, D. Z. I., Lingvay, I., Parsa, A., Rossing, P. R., Sigal, R. J., Afkarian, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916624 · Cited by 391
Solini, A., Giannini, L., Seghieri, M., Vitolo, E., Taddei, S., Ghiadoni, L., & Bruno, R. M. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0621-8 · Cited by 375
van Bommel, E. J. M., Muskiet, M. H. A., van Baar, M. J. B., Tonneijck, L., Smits, M. M., Emanuel, A. L., Bozovic, A., Danser, A. H. J., Geurts, F., Hoorn, E. J., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.013 · Cited by 363
Packer, M., Anker, S. D., Butler, J., Filippatos, G. S., & Zannad, F. M. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.2275 · Cited by 342
Neal, B. C., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Stein, P., Desai, M. G., Shaw, W. C., Jiang, J., Vercruysse, F., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.05.007 · Cited by 341
Self-citationImpact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 265
Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers
Dekkers, C. C. J., Petrykiv, S., Laverman, G. D., Cherney, D. Z., Gansevoort, R. T., & Heerspink, H. J. L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13301 · Cited by 263
Self-citationSAS Macro for Causal Mediation Analysis with Survival Data
Valeri, L., & VanderWeele, T. J. (2015) · Epidemiology · doi:10.1097/ede.0000000000000253 · Cited by 226
Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
Daniele, G., Xiong, J., Solis‐Herrera, C., Merovci, A., Eldor, R., Tripathy, D., DeFronzo, R. A., Norton, L., & Abdul‐Ghani, M. A. (2016) · Diabetes Care · doi:10.2337/dc15-2688 · Cited by 215
ENDOTHELIN: AN IMPORTANT FACTOR IN ACUTE RENAL FAILURE?
Firth, J. D., Raine, A. E. G., Ratcliffe, P. J., & Ledingham, J. G. G. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90243-7 · Cited by 211
The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD
Sato, Y., Feig, D. I., Stack, A. G., Kang, D., Lanaspa, M. A., Ejaz, A. A., Sánchez‐Lozada, L. G., Kuwabara, M., Borghi, C., & Johnson, R. J. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0174-z · Cited by 201
Neal, B., Perkovic, V., Matthews, D. R., Mahaffey, K. W., Fulcher, G., Meininger, G., Erondu, N., Desai, M., Shaw, W., Vercruysse, F., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12829 · Cited by 174
Self-citationLim, V. G., Bell, R. M., Arjun, S., Kolatsi‐Joannou, M., Long, D. A., & Yellon, D. M. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.10.002 · Cited by 166
Petrykiv, S. I., Sjöström, C. D., Greasley, P. J., Xu, J. L., Persson, F., & Heerspink, H. J. L. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10180916 · Cited by 150
Self-citationMediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
Li, J., Woodward, M., Perkovic, V., Figtree, G. A., Heerspink, H. J. L., Mahaffey, K. W., de Zeeuw, D., Vercruysse, F., Shaw, W., Matthews, D. R., et al. (2020) · JACC: Heart Failure · doi:10.1016/j.jchf.2019.08.004 · Cited by 144
Self-citationNeuen, B. L., Ohkuma, T., Neal, B. C., Matthews, D. R., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Li, Q., Jardine, M., Oh, R., et al. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019010064 · Cited by 133
Self-citationTsai, Y., Tsai, J., Chen, S., Chiu, Y., Hwang, S., Hung, C., Chen, T.-H., Kuo, M., & Chen, H. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.06.011 · Cited by 121
Natural Direct and Indirect Effects on the Exposed: Effect Decomposition under Weaker Assumptions
Vansteelandt, S., & VanderWeele, T. J. (2012) · Biometrics · doi:10.1111/j.1541-0420.2012.01777.x · Cited by 99
“Proportion explained”: a causal interpretation for standard measures of indirect effect?
Hafeman, D. M. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp283 · Cited by 98
Yu, Q., Wu, X., Ли, Б., & Scribner, R. A. (2018) · Statistics in Medicine · doi:10.1002/sim.7977 · Cited by 97
Chang, Y., Lei, C., Lin, K., Chang, D., Hsieh, C., & Lee, Y. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2768 · Cited by 66
Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes
Mulder, S., Heerspink, H. J. L., Darshi, M., Kim, J. J., Laverman, G. D., Sharma, K., & Pena, M. J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13823 · Cited by 65
Self-citationFaucon, A., Flamant, M., Metzger, M., Boffa, J., Haymann, J., Houillier, P., Thervet, É., Vrtovsnik, F., Stengel, B., Géri, G., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.06.017 · Cited by 49
Cited by
Sorted by citations
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2020) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 556
Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes
Agarwal, R., Green, J. B., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Mottl, A. K., Rosenstock, J., Rossing, P., Vaduganathan, M., Brinker, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410659 · Cited by 319
Self-citationZannad, F. M., Ferreira, J. P., Butler, J., Filippatos, G. S., Januzzi, J. L., Sumin, M., Zwick, M., Saadati, M., Pocock, S., Sattar, N. A., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac495 · Cited by 202
Apperloo, E. M., Neuen, B. L., Fletcher, R. A., Jongs, N., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Herrington, W. G., Inzucchi, S. E., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00155-4 · Cited by 180
Self-citation
Metadata
- Authors
- Li, J., Neal, B., Perkovic, V., de Zeeuw, D., Neuen, B. L., Arnott, C., Simpson, R., Oh, R., Mahaffey, K. W., & Heerspink, H. J. L.
- Affiliations
- Army Medical University (CN)
- The George Institute for Global Health (GB)
- UNSW Sydney (AU)
- University Medical Center Groningen (NL)
- Royal Prince Alfred Hospital (AU)
- Janssen Research & Development (United States) (US)
- Stanford Medicine (US)
- Corresponding author
- Heerspink, Hiddo J.L.
- ORCID
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 98
- Issue
- 3
- Pages
- 769-777
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W3029576443
- Cited by
- 130
- References
- 41
- Citations by year
- 2026: 8 · 2025: 30 · 2024: 25 · 2023: 21 · 2022: 22 · 2021: 21 · 2020: 3
- FWCI
- 10.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Kidney International (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- Janssen Research & Development
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- canagliflozin, type 2 diabetes, renal protection, kidney disease progression, SGLT2 inhibitors, mediation analysis, urinary albumin-creatinine ratio, erythrocyte concentration, serum uric acid, systolic blood pressure, estimated glomerular filtration rate decline, end-stage renal disease, CANVAS trial
- MeSH terms
- Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Humans, Kidney
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
